glp-1 marketing news Jim Cramer dissects how drugs are disrupting the entire healthcare industry Glucagon-like Peptide 1 (GLP-1) Market
Description
10.2337/dc14-0865 [DOI] [PubMed] [Google Scholar]
This review synthesizes evidence from over 15 peer-reviewed publications (20202026), prioritizing systematic reviews, meta-analyses, and phase 3/4 clinical trials extracted from PubMed
A 2023 study found that patients with cardiovascular disease who were taking semaglutide, the active ingredient in Ozempic and Wegovy, had fewer cardiovascular-related deaths and fewer heart attacks
Tirzepatide (but not semaglutide) has been shown to have the following effects on oral contraception, which were not seen for semaglutide, or any of the less commonly used GLP-1 agonists
